BioAtla, a Phase 2 biotech developing selective antibody therapies for solid tumors, raised $189 million by offering 10.5 million shares at $18, above the range of $15 to $17. The company offered 1.1 million more shares than anticipated. At pricing, BioAtla raised 26% more in proceeds than anticipated.
BioAtla plans to list on the Nasdaq under the symbol BCAB. J.P. Morgan, Jefferies and Credit Suisse acted as lead managers on the deal.
